Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment

Arthritis and Rheumatism

Volumn 63, Issue 12, 2011, Pages 3681-3691

  Lal, Preeti ^a   Su, Zheng ^a   Holweg, Cecile T J ^a   Silverman, Gregg J ^b   Schwartzman, Sergio ^c,d   Kelman, Ariella ^a   Read, Simon ^e   Spaniolo, Greg ^a   Monroe, John G ^a   Behrens, Timothy W ^a   Townsend, Michael J ^a  

^a GENENTECH INC   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^e ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AUTOANTIBODY; C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOGLOBULIN A RHEUMATOID FACTOR ANTIBODY; IMMUNOGLOBULIN G RHEUMATOID FACTOR ANTIBODY; IMMUNOGLOBULIN M RHEUMATOID FACTOR ANTIBODY; INFLIXIMAB; METHOTREXATE; PLACEBO; RHEUMATOID FACTOR; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; FEMALE; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; RHEUMATOID FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 82455163823     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30596     Document Type: Article

References (46)

1. Tak PP, Bresnihan B,. The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis. Arthritis Rheum 2000; 43: 2619-33. (Pubitemid 32001727)
2. Lee DM, Weinblatt ME,. Rheumatoid arthritis. Lancet 2001; 358: 903-11. (Pubitemid 32900579)
3. Goronzy JJ, Weyand CM,. Rheumatoid arthritis. Immunol Rev 2005; 204: 55-73. (Pubitemid 40460493)
4. Combe B,. Progression in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009; 23: 59-69.
5. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 675-81. (Pubitemid 38296553)
6. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371: 987-97. (Pubitemid 351392039)
7. Smolen JS, van der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum 2006; 54: 702-10.
8. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008; 67: 547-54. (Pubitemid 351498439)
9. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000; 43: 1001-9. (Pubitemid 30368176)
10. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81. (Pubitemid 38758544)
11. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54: 1390-400.
12. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806. (Pubitemid 44497758)
13. Martin F, Chan AC,. B cell immunobiology in disease: evolving concepts from the clinic. Annu Rev Immunol 2006; 24: 467-96.
14. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders [SERENE]). Ann Rheum Dis 2010; 69: 1629-35.
15. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35.
16. Leandro MJ, Cooper N, Cambridge G, Ehrenstein MR, Edwards JC,. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford) 2007; 46: 29-36. (Pubitemid 44932780)
17. Kavanaugh A, Rosengren S, Lee SJ, Hammaker D, Firestein GS, Kalunian K, et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 2008; 67: 402-8. (Pubitemid 351281278)
18. Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP,. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis 2008; 67: 917-25. (Pubitemid 351956651)
19. Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM,. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis 2009; 68: 1011-6.
20. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC,. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-20. (Pubitemid 43228639)
21. Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP,. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2377-86. (Pubitemid 44204997)
22. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24. (Pubitemid 18091653)
23. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL,. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-8.
24. Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum 1996; 39: 34-40. (Pubitemid 26036375)
25. DeForge LE, Loyet KM, Delarosa D, Chinn J, Zamanian F, Chuntharapai A, et al. Evaluation of heterophilic antibody blocking agents in reducing false positive interference in immunoassays for IL-17AA, IL-17FF, and IL-17AF. J Immunol Methods 2010; 362: 70-81.
26. Isaacs J, Olech E, Tak P, Deodhar A, Keystone E, Emery P, et al. Autoantibody-positive rheumatoid arthritis patients have enhanced clinical response to rituximab when compared with seronegative patients. Ann Rheum Dis 2009; 68 (Suppl3): 442.
27. Tak P, Cohen S, Emery P, Saadeh C, Vita SD, Donohue J, et al. Clinical response following the first treatment course with rituximab: effect of baseline autoantibody status (RF, anti-CCP). Ann Rheum Dis 2007; 66 Suppl II: ii338.
28. Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Loet XL, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 2011; 63: 933-8.
29. Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007; 47: 1119-28.
30. Roll P, Dorner T, Tony HP,. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 2008; 58: 1566-75. (Pubitemid 351847509)
31. DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 2008; 180: 361-71.
32. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48: 2146-54. (Pubitemid 36959194)
33. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P,. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008; 58: 2993-9.
34. Silverman GJ, Boyle DL,. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: the B-cell roadblock hypothesis. Immunol Rev 2008; 223: 175-85. (Pubitemid 351986172)
35. Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007; 56: 3909-18. (Pubitemid 350262317)
36. Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF, et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 2007; 66: 712-9. (Pubitemid 46846688)
37. Van der Pouw Kraan TC, van Gaalen FA, Kasperkovitz PV, Verbeet NL, Smeets TJ, Kraan MC, et al. Rheumatoid arthritis is a heterogeneous disease: evidence for differences in the activation of the STAT-1 pathway between rheumatoid tissues. Arthritis Rheum 2003; 48: 2132-45. (Pubitemid 36959193)
38. Van der Pouw Kraan TC, van Gaalen FA, Huizinga TW, Pieterman E, Breedveld FC, Verweij CL,. Discovery of distinctive gene expression profiles in rheumatoid synovium using cDNA microarray technology: evidence for the existence of multiple pathways of tissue destruction and repair. Genes Immun 2003; 4: 187-96. (Pubitemid 38967596)
39. Van Baarsen LG, Wijbrandts CA, Timmer TC, van der Pouw Kraan TC, Tak PP, Verweij CL,. Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood. Arthritis Rheum 2010; 62: 1602-7.
40. Van Zeben D, Breedveld FC,. Prognostic factors in rheumatoid arthritis. J Rheumatol Suppl 1996; 44: 31-3. (Pubitemid 26094644)
41. Eklund CM,. Proinflammatory cytokines in CRP baseline regulation. Adv Clin Chem 2009; 48: 111-36.
42. Van Gaalen FA, Linn-Rasker SP, van Venrooij WJ, de Jong BA, Breedveld FC, Verweij CL, et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004; 50: 709-15. (Pubitemid 38326168)
43. Quinn MA, Gough AK, Green MJ, Devlin J, Hensor EM, Greenstein A, et al. Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome. Rheumatology (Oxford) 2006; 45: 478-80.
44. Klareskog L, Widhe M, Hermansson M, Ronnelid J,. Antibodies to citrullinated proteins in arthritis: pathology and promise. Curr Opin Rheumatol 2008; 20: 300-5. (Pubitemid 351483320)
45. Nishimura K, Sugiyama D, Kogata Y, Tsuji G, Nakazawa T, Kawano S, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007; 146: 797-808. (Pubitemid 351650500)
46. Van Zeben D, Hazes JM, Zwinderman AH, Cats A, van der Voort EA, Breedveld FC,. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 1992; 51: 1029-35.